Skip to content
Search

Latest Stories

Novo Nordisk warns of supply constraints on its best-selling diabetes drug

Danish drug developer Novo Nordisk on Wednesday (February 1) warned of supply constraints on its best-selling drug.

The company, which develops diabetes and obesity drugs, said it expected "periodic supply constraints" this year, partly driven by higher than expected demand for its blockbuster diabetes drug, Ozempic, and manufacturing constraints.


"Supply of Ozempic cannot keep up with demand in some markets," Novo's Chief Financial Officer Karsten Munk Knudsen told journalists on Wednesday, but said Ozempic was available in the United States, the firm's biggest single market.

Shortages of human growth hormone would also cause sales in its rare disease franchise to drop by a "mid-single digit" percentage in 2023, as its Norditropin drug would be out of stock in certain markets, Knudsen said.

Sales of Novo Nordisk's new obesity drug, Wegovy, grew nearly 300 per cent in local currencies last year, despite having faced serious supply issues throughout the year.

More For You

Trump signs executive order to accelerate US-based pharmaceutical manufacturing plants

US president Donald Trump

Pic credit: Getty Images

Trump signs executive order to encourage US drug manufacturing

US president Donald Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharmaceutical plants in the country, as part of new regulations to encourage domestic manufacturing.

The order directs the US Food and Drug Administration to streamline reviews and work with domestic manufacturers to provide early support before facilities come online.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less
Many patients report inaccuracies or missing details in their NHS medical records

Inaccurate information can result in serious harm or even death, warns Healthwatch England.

Image Credit: Getty Images

1 in 4 adults have spotted errors in their NHS medical records, survey finds

Healthwatch England has raised the alarm over the risks posed by inaccurate medical records as research reveals widespread errors in NHS patient information.

Commissioned by Healthwatch England and conducted by BMG Research, the survey polled a representative sample of 1,800 adults in England between 24 and 27 March 2025.

Keep ReadingShow less